Abstract
The amyloid-β (Aβ) peptides and in particular the longer, highly amyloidogenic isoform Aβ42 are believed by many to be the central disease-causing agents in Alzheimers disease (AD). Consequently, academic and pharmaceutical laboratories have focused on elucidating the mechanisms of Aβ production and developing strategies to diminish Aβ formation for treatment or prevention of AD. The most substantial advances have been made with respect to inhibitors of the γ-secretase enzyme, which catalyzes the final step in the generation of Aβ from the amyloid precursor protein (APP). Highly potent γ-secretase inhibitors which suppress production of all Aβ peptides are available today. However, due to the promiscuous substrate specificity of γ-secretase and its essential role in the NOTCH signaling pathway overt mechanismbased toxicity has been observed in preclinical studies of γ-secretase inhibitors. For that reason, specific blockage of Aβ42 production might be preferable over non-discriminatory γ-secretase inhibition but small molecule inhibitors of Aβ42 production have remained elusive until recently. This has changed with the discovery that certain non-steroidal antiinflammatory drugs (NSAIDs) including ibuprofen possess preferential Aβ42-lowering activity. These compounds seem to offer a window of modulation where Aβ42 production is potently inhibited whereas processing of the NOTCH receptor and other g-secretase substrates remains unaffected. The Aβ42-lowering activity of NSAIDs is not related to inhibition of cyclooxygenases and can be dissociated from the anti-inflammatory properties of this class of drugs. Ongoing efforts concentrate on uncovering the mechanism of action and improving potency and brain permeability of Aβ42-lowering compounds. Hopes are high that in the near future this will lead to the development of clinically viable compounds which selectively target Aβ42 as a key molecule in the pathogenesis of AD.
Keywords: amyloid precursor protein (APP), transmembrane domain (TMD), NOTCH signaling, NSAIDs, pro-inflammatory, Non-COX
Current Pharmaceutical Design
Title: Selective Modulation of Aβ42 Production in Alzheimers Disease: Non-Steroidal Anti-Inflammatory Drugs and Beyond
Volume: 12 Issue: 33
Author(s): Stefanie Leuchtenberger, Dirk Beher and Sascha Weggen
Affiliation:
Keywords: amyloid precursor protein (APP), transmembrane domain (TMD), NOTCH signaling, NSAIDs, pro-inflammatory, Non-COX
Abstract: The amyloid-β (Aβ) peptides and in particular the longer, highly amyloidogenic isoform Aβ42 are believed by many to be the central disease-causing agents in Alzheimers disease (AD). Consequently, academic and pharmaceutical laboratories have focused on elucidating the mechanisms of Aβ production and developing strategies to diminish Aβ formation for treatment or prevention of AD. The most substantial advances have been made with respect to inhibitors of the γ-secretase enzyme, which catalyzes the final step in the generation of Aβ from the amyloid precursor protein (APP). Highly potent γ-secretase inhibitors which suppress production of all Aβ peptides are available today. However, due to the promiscuous substrate specificity of γ-secretase and its essential role in the NOTCH signaling pathway overt mechanismbased toxicity has been observed in preclinical studies of γ-secretase inhibitors. For that reason, specific blockage of Aβ42 production might be preferable over non-discriminatory γ-secretase inhibition but small molecule inhibitors of Aβ42 production have remained elusive until recently. This has changed with the discovery that certain non-steroidal antiinflammatory drugs (NSAIDs) including ibuprofen possess preferential Aβ42-lowering activity. These compounds seem to offer a window of modulation where Aβ42 production is potently inhibited whereas processing of the NOTCH receptor and other g-secretase substrates remains unaffected. The Aβ42-lowering activity of NSAIDs is not related to inhibition of cyclooxygenases and can be dissociated from the anti-inflammatory properties of this class of drugs. Ongoing efforts concentrate on uncovering the mechanism of action and improving potency and brain permeability of Aβ42-lowering compounds. Hopes are high that in the near future this will lead to the development of clinically viable compounds which selectively target Aβ42 as a key molecule in the pathogenesis of AD.
Export Options
About this article
Cite this article as:
Leuchtenberger Stefanie, Beher Dirk and Weggen Sascha, Selective Modulation of Aβ42 Production in Alzheimers Disease: Non-Steroidal Anti-Inflammatory Drugs and Beyond, Current Pharmaceutical Design 2006; 12 (33) . https://dx.doi.org/10.2174/138161206778793029
DOI https://dx.doi.org/10.2174/138161206778793029 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Muscle Atrophy Classification: The Need for a Pathway-Driven Approach
Current Pharmaceutical Design Peripheral Arterial Disease - The Forgotten Risk Factor
Vascular Disease Prevention (Discontinued) Mechanisms of Enhanced Vasoconstriction in the Mouse Model of Atherosclerosis: the Beneficial Effects of Sildenafil
Current Pharmaceutical Biotechnology Dietary Small Molecules and Large-Scale Gene Expression Studies: An Experimental Approach for Understanding their Beneficial Effects on the Development of Malignant and Non-Malignant Proliferative Diseases
Current Medicinal Chemistry Nutritional Control, Gene Regulation, and Transformation of Vascular Smooth Muscle Cells in Atherosclerosis
Cardiovascular & Hematological Disorders-Drug Targets Effect of Dipeptidyl Peptidase-4 Inhibitors on Plasma Adiponectin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Current Medicinal Chemistry PERK-opathies: An Endoplasmic Reticulum Stress Mechanism Underlying Neurodegeneration
Current Alzheimer Research Potential Application of 5-Aryl-Substituted 2-Aminobenzamide Type of HDAC1/2- Selective Inhibitors to Pharmaceuticals
Current Pharmaceutical Design Vascular Dysfunction and Insulin Resistance in Aging
Current Vascular Pharmacology Mechanisms of Platelet Activation in Acute Coronary Syndromes
Current Vascular Pharmacology The Renal Outer Medullary Potassium Channel (ROMK): An Intriguing Pharmacological Target for an Innovative Class of Diuretic Drugs
Current Medicinal Chemistry Myocardial Structure and Matrix Metalloproteinases
Current Topics in Medicinal Chemistry (Pro)renin Receptor as a New Drug Target
Current Pharmaceutical Design Anti-atherosclerotic Effects of Spice-Derived Phytochemicals
Current Medicinal Chemistry Inflammation as Therapeutic Objective in Stroke
Current Pharmaceutical Design Inflammatory Mechanisms in Myocardial Infarction
Current Drug Targets - Inflammation & Allergy LGE-MRI in the Assessment of Left-ventricular Remodelling in Myocarditis
Current Medical Imaging Optimal Medical Therapy for Coronary Artery Disease in 2011 – Perspectives from the STICH Trial
Cardiovascular & Hematological Agents in Medicinal Chemistry NRF2-Dependent Glutamate-L-Cysteine Ligase Catalytic Subunit Expression Mediates Insulin Protection Against Hyperglycemia-Induced Brain Endothelial Cell Apoptosis
Current Neurovascular Research Current Updates in the Medical Management of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery